2017 American Transplant Congress
Early and Late Antibody Mediated Rejection and Mixed Acute Rejection Are Clinically Distinct and Demonstrate Biologic Differences in Immunodominant Donor Specific Antibody Characteristics.
1U of Cincinnati, Cincinnati; 2The Christ Hospital, Cincinnati
Early and late antibody mediated rejection (AMR) and mixed acute rejection (MAR) possibly result from fundamentally different immunologic processes. DSA mediates direct injury by complement-dependent…2017 American Transplant Congress
HLA Donor-Specific Antibody (DSA) Negative Antibody-Mediated Rejection (AMR): Incidence, Treatment and Outcomes.
Background: Banff 2013 criteria for the diagnosis of antibody-meditated rejection (AMR) in kidney transplants require the presence of donor-specific antibody (DSA). Clinical significance of histological…2017 American Transplant Congress
Tocilizmab (Anti-IL-6R) Treatment (TCZ-Rx) Reduced Total IgG Levels Including Anti-HLA IgG: Analysis of IgG Subclasses (IgG1-IgG4) and Anti-HLA IgG Subclasses Show Similar Reductions in All Subclasses from Patients with DSA+ Chronic Antibody-Mediated Rejection (CABMR).
Background: DSA+ CABMR constitutes the major cause for renal allograft loss in the U.S. Currently there are no approved therapies. We have reported TCZ use…2017 American Transplant Congress
A Novel Role for MyD88 Signaling Downstream from Toll-Like Receptors in B Cells Responding to Blood Group Antigens.
Hiroshima University, Hiroshima, Japan
[Introduction]Although there is some empirical evidence that severe infectious complications provoke refractory AMR following ABO-incompatible transplantations (ABOi-Tx), its mechanism remains unclear. Here, we investigated a…2016 American Transplant Congress
Bortezomib Impacts Tenascin mRNA in PBMNCs.
Medical University of South Carolina, Charleston.
Tenascin (TNC) is a gene thought to play a role in the binding of receptors and syndecan binding. Syndecans are signal transmembrane proteins that act…2016 American Transplant Congress
The Effect of Tocilizmab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.
Background: Antibody-mediated rejection (ABMR) is a major obstacle for successful transplant in HS patients. TCZ has anti-B cell and anti-inflammatory properties. We have reported its…2016 American Transplant Congress
The Early Outcomes of Bortezomib Therapy in Patients with Late Antibody Mediated Rejection in Renal Transplantation.
Although several strategies for treating antibody mediated rejection (AMR) in renal transplants have been investigated, the formation of donor-specific antibodies (DSA) and ongoing AMR contribute…2016 American Transplant Congress
Ameliorating Progression of Allograft Vasculopathy by Targeting the T Follicular Helper Cell Subset.
Department of Surgery, University of Cambridge, Cambridge, United Kingdom.
BACKGROUNDDevelopment of long-lived alloantibody is closely linked with chronic rejection and graft failure. We examined in a murine model of antibody-mediated rejection (AMR) if targeting…2016 American Transplant Congress
Enabled PRA and Precision PRA: Alternatives to cPRA as Desensitization Trial Endpoints.
U of Cincinnati, Cincinnati; Mayo Clinic Scottsdale, Scottsdale.
Transplant (Transplant) rate is an optimal endpoint in desensitization (DS) trials in HLA sensitized Txp candidates, however, for waitlisted Txp candidates, wait time heterogeneity compromises…2016 American Transplant Congress
Tacrolimus as a Tool for Intracellular Assessment of von Willebrand Factor Production by Activated Human Glomerular Endothelial Cells.
Renal Division, University Health Center (CHU) of Quebec, Laval University, Quebec, QC, Canada.
Background: Von Willebrand factor (vWF) is a prothrombotic mediator stored in intracytoplasmic granules within endothelial cells and is released by endothelial exocytosis, leading to microangiopathic…
- « Previous Page
- 1
- …
- 41
- 42
- 43
- 44
- 45
- …
- 57
- Next Page »